ClinicalTrials.Veeva

Menu

Bariatric Endoscopy and NAFLD

U

University of Ostrava

Status

Unknown

Conditions

Liver Fibrosis
Obesity
NAFLD
Liver Steatosis

Treatments

Procedure: bariatric endoscopy, mainly intragastric baloons, plication of stomach too

Study type

Interventional

Funder types

Other

Identifiers

NCT04669470
08_RVO-FNOs_2020

Details and patient eligibility

About

Find out how bariatric endocopy will influence clinical course of non alcoholic fatty liver disease.

Full description

The study will test and investigate the impact of bariatric endoscopy (various types of intragastric balloons, endoscopic sleeve gastroplasty, aspiration therapy) on components of the metabolic syndrome in obese patients, especially on influencing non-alcoholic steatosis and steatohepatitis and signs of liver fibrotization and weight reduction. The method consists in performing a mini-invasive endoscopic procedure and, as a result, in reduced food intake.

Current state of knowledge:

Based on data evaluated according to EBM (Evidence Based Medicine), it is an indisputable fact that bariatric methods have a demonstrable effect not only on improving the parameters and regression of many metabolic syndromes, but also improve the course of non-alcoholic fatty liver disease (NAFLD). It is this nosological unit that is becoming the dominant cause of liver disease in developed countries and has two subunits, where simple hepatic steatosis (NAFL) is considered a benign disease, while the second, where fat accumulation in the liver is associated with the inflammatory process called non-alcoholic steatohepatitis (NASH). ) has serious consequences for the liver with the development of fibrotization leading to cirrhosis with all its adverse effects. Recently, however, it has been shown that even simple steatosis is not as benign as it seemed, but carries an independent risk for the patient due to an increased incidence of cardiovascular diseases, oncological manifestations and a higher incidence of metabolic syndrome manifestations. Classical bariatric endoscopy carries a number of risks associated with the patient for the surgical procedure, however, we also have less invasive methods of gradually more and more developing endoscopy and dreams of associated bariatric procedures with many times lower risk for the patient.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

To be eligible for participation in this study, subjects must conform to the following inclusion criteria:

  1. Age between 21-64 years;
  2. BMI >30 Kg/m2
  3. Must be able to comply with all study requirements for the duration of the study as outlined in the protocol. This includes complying with the visit schedule as well as study specific procedures such as: clinical assessment , endoscopy, radiography, as well as laboratory investigations.
  4. Must be able to understand and be willing to provide written informed consent.

Exclusion criteria

  • Subjects meeting any of the following exclusionary criteria cannot be enrolled in the study:

    1. Achalasia and any other esophageal motility disorders
    2. Heart diseases: unstable angina, myocardial infarction within the past year, or heart disease classified within the New York Heart Association's Class III or IV functional capacity.
    3. Hypertension: uncontrolled hypertension during last 3 month
    4. Severe renal, hepatic, pulmonary disease or cancer;
    5. GIT stenosis or obstruction
    6. Pregnancy or breastfeeding
    7. Impending gastric surgery 60 days post intervention;
    8. Currently participating in other study
    9. Celiac disease
    10. History of bariatric surgery
    11. Chronic or recent acute pancreatitis
    12. Type 2 diabetes with insuline medication or type 1 diabetes
    13. Hematologic disease or disease with impairment of hemocoagulation
    14. Decompensated psychiatric disease
    15. Autoimmune disease with chronic glucocorticoid or imunosupressive medications
    16. Uncontroled disease of thyroid gland
    17. Excesive abuse of addictive substances such alcohol or other

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

Single Blind

100 participants in 2 patient groups

Group with adjustable IGB
Active Comparator group
Treatment:
Procedure: bariatric endoscopy, mainly intragastric baloons, plication of stomach too
Group with nin-adjustable IGB
Active Comparator group
Treatment:
Procedure: bariatric endoscopy, mainly intragastric baloons, plication of stomach too

Trial contacts and locations

1

Loading...

Central trial contact

Adam Vasura

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems